Department of Anatomy, College of Chinese Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Biomed Pharmacother. 2023 Dec;168:115752. doi: 10.1016/j.biopha.2023.115752. Epub 2023 Oct 22.
Cardiovascular disease (CVD) remains the leading cause of death and disability globally. A wide range of CVDs have been reported, each of which diverges significantly, exhibiting sophisticated types of pathogenesis (e.g., inflammatory, oxidative stress, and disorders in cardiomyocyte metabolism). Compared with conventional treatments in modern medicine, traditional Chinese medicine (TCM) can exhibit comparative advantages in the treatment of CVDs. TCM can be utilized to develop effective strategies for addressing the challenges of CVD, with fewer side effects and higher therapeutic efficiency. Astragaloside IV (AS-IV) has been confirmed as one of the major active ingredients found in Astragalus membranaceus (a Chinese herbal medicine that has been extensively employed clinically for the treatments of CVDs). Since recent studies have shown that AS-IV in CVD treatments has achieved promising results, the substance has aroused great attention and further discussions in the field. The present review aims to summarize the recent pharmacological advances in employing AS-IV in the treatment of CVDs.
心血管疾病（CVD）仍然是全球范围内死亡和残疾的主要原因。已经报道了广泛的 CVD，每种 CVD 都有很大的差异，表现出复杂的发病机制类型（例如炎症、氧化应激和心肌细胞代谢紊乱）。与现代医学的传统治疗方法相比，中药（TCM）在治疗 CVD 方面可以表现出比较优势。TCM 可用于制定有效的策略来应对 CVD 的挑战，具有较少的副作用和更高的治疗效率。黄芪甲苷（AS-IV）已被确认为中药黄芪（一种临床上广泛用于治疗 CVD 的中草药）中的主要活性成分之一。由于最近的研究表明 AS-IV 在 CVD 治疗中取得了有希望的结果，因此该物质在该领域引起了极大的关注和进一步的讨论。本综述旨在总结 AS-IV 在治疗 CVD 中的药理学最新进展。
